<SEC-DOCUMENT>0001628280-24-009006.txt : 20240305
<SEC-HEADER>0001628280-24-009006.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305171030
ACCESSION NUMBER:		0001628280-24-009006
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240305
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		24722166

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20240305.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20240305</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20240305.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-05</xbrli:startDate><xbrli:endDate>2024-03-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iab5fb63bec3e4480a4cd294ae073242e_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 5, 2024</ix:nonNumeric> (March 5, 2024)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2525 West End Avenue, Suite 950</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iab5fb63bec3e4480a4cd294ae073242e_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December&#160;31, 2023.  A copy of the press release is attached as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2023q4ex991earningsrelease.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Financial Statements and Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(d)  Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"/><td style="width:18.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q4ex991earningsrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023q4ex991earningsrelease.htm">Press release dated March 5, 2024</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iab5fb63bec3e4480a4cd294ae073242e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March&#160;5, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2023q4ex991earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1e878e7b01214745afcdbc346f47cf49_182"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:407px"></div><div style="text-align:center"><font><br></font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Reports </font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> Annual 2023 Financial Results</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2023 highlights include expanded FDA approval and new study publications</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NASHVILLE, TENNESSEE (Tuesday, March 5, 2024) &#8211; Cumberland Pharmaceuticals Inc. (NASDAQ&#58; CPIX)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland ended the year with $82 million in total assets &#8211; including $18 million in cash, $53 million in liabilities and $30 million of shareholders&#8217; equity.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements,&#8221; said Cumberland Pharmaceuticals CEO A.J. Kazimi. &#8220;We were pleased to expand the labeling for our Caldolor product to include use in infants, while continuing to build our other brands and progress our clinical programs.&#8221;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland will report its 2023 financial results and provide a Company update via a conference call today, March 5, 2024, at 4&#58;30 p.m. Eastern Time.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">HIGHLIGHTS FOR THE YEAR INCLUDE&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Mission Statement </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In 2023, Cumberland refined its mission statement to better capture the spirit of the Company. It now reads&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">working together to provide unique products that improve the quality of patient care.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In designing this statement, Cumberland considered several factors. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company wanted its mission to address the constituencies it serves, which include patients in need of care, as well as health care providers and its employees, shareholders, partners and community.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It needed to reflect Cumberland&#8217;s culture, where teamwork is prized, emphasized and expected &#8211; in order to achieve the company&#8217;s goals.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It also demonstrates Cumberland&#8217;s focus on developing, acquiring and distributing differentiated brands.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">And finally, Cumberland wanted to emphasize that the patient is at the core of everything it does. Its collective efforts are directed at providing unique products that serve as better alternatives for poorly met medical needs.</font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> FDA Approval for Treating Infants and Supporting Study Publication </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The FDA approved expanded labeling for Cumberland&#8217;s Caldolor product, an intravenously delivered formulation of ibuprofen, to include its use in infants. The non-narcotic agent may now be administered for the treatment of pain and fever in patients 3 to 6 months of age. With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants that is delivered through injection.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland also announced positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns, published in the journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Drugs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The results of the study support the growing body of evidence that demonstrates Caldolor is a safe therapeutic option available to practitioners for the treatment of fever and pain in infants, children and adults.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Federal NOPAIN Act</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In early 2023, the federal NOPAIN Act was passed, which the Company expects, will provide special, favorable reimbursement for non-opioid products like Caldolor. Cumberland submitted a request to the Centers for Medicare &#38; Medicaid Services (CMS), to include Caldolor in the favorable reimbursement and expects to learn more this year in preparation for the Act&#8217;s implementation in 2025.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expanded Oncology Sales Division </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland expanded its oncology sales division as it works to deliver its newest brand &#8211; Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8211; to help cancer patients tolerate their chemotherapy treatments. Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Pediatric Study Results Published </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland announced a new publication in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Antimicrobial Agents and Chemotherapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of its Vibativ product in children 2 to 17 years of age. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections caused by certain gram-positive bacteria. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The results of the study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2023 Sustainability Metrics </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland updated its annual sustainability metrics, detailing the company&#8217;s activities pertaining to its environmental, social and governance matters. Cumberland reported its key findings for 2023, including providing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3 million doses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of its FDA-approved products to patients and safely disposing of nearly 6,000 pounds of damaged and expired products. Additionally, Cumberland had no products recalled and no clinical trials terminated due to failure to practice good clinical standards in 2023.</font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Development Programs</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Throughout 2023, Cumberland continued to progress its pipeline of innovative products designed to improve patient care and patients&#8217; quality of life. Cumberland's ifetroban product candidate &#8211; a potent and selective thromboxane receptor antagonist &#8211; is being evaluated in three Phase II clinical trials for patients with a series of unmet medical needs. It has now been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in those individuals. Patient enrollment is well underway in two of those Company-sponsored Phase II clinical programs.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The first clinical program involves patients with Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The other clinical program is evaluating ifetroban in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, or DMD. DMD is a rare and fatal genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles. Cumberland is sponsoring the FIGHT DMD&#8482; trial, a multicenter, randomized, placebo-controlled Phase II study enrolling patients across 10 centers in the United States that specialize in DMD. The Company has completed enrollment in the younger age group of patients and now is working to finish enrollment in the older patient group with DMD. The FDA has provided grant awards of over $1 million to support this study.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland is also developing an oral capsule to treat Idiopathic Pulmonary Fibrosis, or IPF, the most common form of progressive fibrosing interstitial lung disease. Following FDA clearance of its investigational new drug application in May 2023, the Company is now in the process of initiating its Phase II FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the United States. Recent studies have shown ifetroban can both prevent and enhance resolution of lung fibrosis in multiple preclinical models.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company&#8217;s plan going forward is to complete each of its company-sponsored studies, analyze their final data, announce top-line results and decide on the best development path for the registration of ifetroban, which the Company continues to believe has the potential to benefit many patients with orphan diseases that represent unmet medical needs.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINANCIAL RESULTS&#58;</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Revenue&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For 2023, net revenues were $40 million and included $16 million for Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $8.8 million for Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $8.1 million for Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and $4.3 million for Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Total operating expenses for 2023 were $49.1 million.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Income (Loss)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The net loss for the fourth quarter of 2023 and the year ended December 31, 2023, was approximately $6.3 million.  Results include a one time non-cash charge to intangible assets of $3.3 million associated with a product discontinuation.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adjusted earnings&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adjusted earnings for the year ended December 31, 2023, were $2.4 million, or $0.17 a share. The adjusted earnings calculation does not include the benefit of the $2.3 million of Vibativ and Sancuso cost of goods, which were received as part of each product&#8217;s acquisition. </font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Balance Sheet&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> At December 31, 2023, Cumberland had $82 million in total assets, including $18 million in cash and cash equivalents. Liabilities totaled $53 million, including $12.8 million on the company&#8217;s credit facility. Total shareholders&#8217; equity was $30 million at December 31, 2023.</font></div><div><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i1e878e7b01214745afcdbc346f47cf49_221"></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EARNINGS REPORT CALL&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland will report its 2023 financial results via a conference call today, March 5, 2023, at 4&#58;30 p.m. Eastern Time. To participate in the call, please register at </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BI77538b1a0c52414b9e2772846f5498ae</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a &#8220;Call Me&#8221; option to have the system automatically call them at the start of the conference. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A replay of the call will be available for one year and can be accessed via Cumberland&#8217;s website or by visiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;edge.media-server.com&#47;mmc&#47;p&#47;eubuwzon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ABOUT CUMBERLAND PHARMACEUTICALS&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The company&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Omeclamox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-Pak</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">granisetron) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. Investigational new study applications have been cleared by the FDA enabling Cumberland to launch clinical studies in each of these areas.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company&#8217;s website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (acetylcysteine) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.acetadote.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (ibuprofen) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.caldolor.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (lactulose) Oral Solution</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.kristalose.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Omeclamox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-Pak (omeprazole, clarithromycin, amoxicillin)</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.omeclamox.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">granisetron) Transdermal System</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately and&#47;or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient&#8217;s bloodstream. It can be worn for up to seven days in a row for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.sancuso.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (conivaptan hydrochloride) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vaprisol.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (telavancin) for Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vibativ.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ABOUT CUMBERLAND EMERGING TECHNOLOGIES&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland Emerging Technologies, Inc. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cet-fund.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET&#8217;s Life Sciences Center provides laboratory space, equipment and infrastructure for CET&#8217;s activities and other early-stage life sciences ventures.</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FORWARD LOOKING STATEMENTS&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company&#8217;s intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;look forward&#8221; and other comparable terms or the negative thereof. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company&#8217;s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), as well as the Company&#8217;s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="margin-top:8pt;text-align:center"><font><br></font></div><div style="margin-top:8pt;text-align:center"><font><br></font></div><div style="margin-top:8pt;padding-left:85.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.713%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Contact&#58;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media Contact&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayla Simpson</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molly Aggas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dalton Agency</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615) 255-0068</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704) 641-6641</font></td></tr></table></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- MORE -</font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e878e7b01214745afcdbc346f47cf49_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December&#160;31, 2023 and 2022 </font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:465.75pt"><tr><td style="width:1.0pt"></td><td style="width:303.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,321,624&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,758,176&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,163,681&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,248&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,978&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,714,410&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,870,210&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804,529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,527,167&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,903&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,607,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,674,394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,692,921&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520,661&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,776,075&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,925,158&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,037,629&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,819,011&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,092&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,596,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,982,249&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,579,832&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,784,144&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296,247&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,453,566&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585,019&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,516,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,951,152&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8211; no par value&#59; 100,000,000 shares authorized&#59; 14,121,833 and 14,366,616 shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,091,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,474,973&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated earnings (deficit)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,488,161)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,208,841)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,603,441&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,266,132&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343,572)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292,126)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,259,869&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,974,006&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,776,075&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,925,158&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e878e7b01214745afcdbc346f47cf49_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,353,066&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123,680&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,552,507&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529,983&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,118,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,379,434&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,451,765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,660,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,753&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405,841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,834,229&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,688,924&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,439,184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507,678&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,651,915&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,539,155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,102,648&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,532,305&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,401,484&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,107,168&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,715,878&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,179,239)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,277,804)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,554,661)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704,929)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,696&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,854&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,405&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,871&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - settlement</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - insurance proceeds</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,800&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,792)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,456)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667,861)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585,995)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,277,031)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,411,564)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,284,997)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,581,189)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,956)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,150)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,769)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,850)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,301,987)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,459,714)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,967&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,446&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291,020)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,440,729)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,279,320)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,164,270&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800,772&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,164,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298,774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e878e7b01214745afcdbc346f47cf49_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2023 and 2022</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:64.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flows provided by  operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935,954&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,328,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,343,842&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use asset</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,503&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,243,185)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,088,296)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,736)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,523&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,237&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash gain on RediTrex transaction</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,882)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on receipt of life insurance policies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346,800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611,330)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404,949&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,115,640)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,143)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,684&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,405,363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,519&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,536,076&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,131,453)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,659&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093,821&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453,396&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,268)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,148)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance policy proceeds received</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,783)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,971,662)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of RediTrex</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of patent litigation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,757&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,500,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,695)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,674,456)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,475,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,900,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on line of credit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,890,856)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,700,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made in connection with repurchase of common shares</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(740,533)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,053,042)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash settlement of contingent consideration</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,268,083)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,208,744)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,424,472)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061,786)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,436,346)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,282,846)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,040,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,321,624&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e878e7b01214745afcdbc346f47cf49_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reconciliation of Net Income (Loss) Attributable to Common Shareholders to Adjusted Earnings (Loss) and Adjusted Diluted Earnings (Loss) Per Share</font></div><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,291,020)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,440,729)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Net income (loss) at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,967&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,301,987)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,459,714)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,150&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,577,109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,483&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,894&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,905&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-down of expired inventory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,380&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,000)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,696)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,792&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss)  Per Share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508,236)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,036)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,164,270&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,401,432&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,279,320)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Net income loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,330,766)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,328,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,040&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,503&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-down of expired inventory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,380&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on insurance proceeds</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346,800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611,330)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,854)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,405)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,861&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,995&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d) (e)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394,046&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050,067&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,526,400&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,809,257&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company provided the above adjusted supplemental financial performance measures, which are considered &#8220;non-GAAP&#8221; financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The definition of these supplemental measures may differ from similarly titled measures used by others.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company&#8217;s reported results of operations, management encourages investors to review the Company&#8217;s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland&#8217;s management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company&#8217;s operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company&#8217;s operating results. Management believes that presenting these supplemental measures provides useful information about the Company&#8217;s underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include&#58; depreciation, amortization, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company&#8217;s operating performance.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company defines these supplemental financial measures as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12.53pt">Adjusted Earnings&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense.  The definition of Adjusted Earnings has been changed to include all gains and losses, as gains are occurring more frequently for the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The financial information presented for the year ended December&#160;31, 2022, has been adjusted to be consistent with the current year presentation.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)  Includes $3.3 million impairment loss on intangible assets.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)  Represents the share-based compensation of Cumberland.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)  Represents the write-down of expired inventory.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) Year-to-date Adjusted Earnings includes a litigation settlement based on two $500,000 milestone payments due to the Company for the license associated with its Vibativ product.</font></div><div style="margin-top:8pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)  Year-to-date Adjusted Earnings includes a gain on the refund of 2022 and 2023 FDA fees in the amount of $2.8 million.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Adjusted Diluted Earnings Per Share&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20240305.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:afe7b2fd-6dea-484a-a869-9805552dd978,g:ebecc39a-dfea-4901-9f2d-9cfd53aa8cac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20240305" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20240305">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20240305_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20240305_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20240305_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:afe7b2fd-6dea-484a-a869-9805552dd978,g:ebecc39a-dfea-4901-9f2d-9cfd53aa8cac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_244c42f6-ff01-4345-8bcb-5136ae257572_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9ba43963-0055-4706-a61e-8ff100a0a482_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c5d6483c-0a6b-4f30-bb98-ddb6ec1bc9d3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6eafdb0e-267d-4b4e-b9f6-bca9b9d7f78c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ffc2be5e-4c3f-4dbd-92f1-71579ff508d1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b34f9af6-d1bb-4da9-8ad7-9e2a5cd70338_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4ba2eb45-5676-4a37-bdd6-db14a0e85dd0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7b14f629-4129-425a-b155-88225c2888dc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8e3cdff4-415e-422c-9bc3-e692cd0c9094_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b1b2a891-7b2f-44ce-8d20-a7be1118965c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ade5dac8-26f1-425b-a955-cf7f6a4c6a29_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d2cb4983-f2c9-4740-9853-74dba0035610_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_12067db9-695c-47a2-ad91-8ccc74eeb326_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2c50bf1f-1ea6-4ef2-9279-375f6000c48f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8ead52e1-3376-4f82-83d3-4b0dc68ee8d3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4d63e931-0457-436d-a719-e514803f8e6e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_84b74743-326d-4b36-9edc-690748176c43_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_498d8a27-d83d-4c29-946c-dc777d585f6d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_803899ca-ebd4-49ef-a86b-b058c213a824_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f5873fa1-9493-40ce-9f15-499888d0fde3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8631510b-ec5c-4f53-8aba-1ad802437b73_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_56cabeee-0cf0-47b6-a99d-fc1156faa61d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2402a13d-6f77-4438-98e3-ad4065fe90ff_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20240305_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:afe7b2fd-6dea-484a-a869-9805552dd978,g:ebecc39a-dfea-4901-9f2d-9cfd53aa8cac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20240305.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8c02ca8f-a82c-491e-ae2d-15ed278f332a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_DocumentType_8c02ca8f-a82c-491e-ae2d-15ed278f332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c7466d7d-fe2c-4bb8-8bba-bd396f81d856" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_DocumentPeriodEndDate_c7466d7d-fe2c-4bb8-8bba-bd396f81d856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6f303cb0-a2cd-4229-bf71-9fb4662bf53d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityRegistrantName_6f303cb0-a2cd-4229-bf71-9fb4662bf53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_146a2503-f239-4bc3-884f-f58f21daa8f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityCentralIndexKey_146a2503-f239-4bc3-884f-f58f21daa8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_207a2328-714a-42fe-ab70-b2eb81fc8016" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_AmendmentFlag_207a2328-714a-42fe-ab70-b2eb81fc8016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cbf13d16-53e2-447f-ad06-31a0f98475ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cbf13d16-53e2-447f-ad06-31a0f98475ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fc1d8225-90d8-4f52-8df4-de3a8ea7a396" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityFileNumber_fc1d8225-90d8-4f52-8df4-de3a8ea7a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_45284753-6ea4-4894-a4a2-55ad5e6a944f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityTaxIdentificationNumber_45284753-6ea4-4894-a4a2-55ad5e6a944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f3c2ca81-cfe6-4b50-8c0c-be03beb959ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_CityAreaCode_f3c2ca81-cfe6-4b50-8c0c-be03beb959ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f2f6ef85-9a4e-48e8-a8c5-4ba285a0b7eb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_LocalPhoneNumber_f2f6ef85-9a4e-48e8-a8c5-4ba285a0b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_37759757-b642-40a4-a1ae-9e5854a3eea8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_WrittenCommunications_37759757-b642-40a4-a1ae-9e5854a3eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_09180057-52f1-46b7-8080-41ad34353797" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_SolicitingMaterial_09180057-52f1-46b7-8080-41ad34353797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_108b2f90-69c1-4e9b-bcc1-0e181d9f5742" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_PreCommencementTenderOffer_108b2f90-69c1-4e9b-bcc1-0e181d9f5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2f941056-f930-4216-9538-2d057125f169" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2f941056-f930-4216-9538-2d057125f169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e4eae791-2924-469f-a1ae-54c0163ffd10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_Security12bTitle_e4eae791-2924-469f-a1ae-54c0163ffd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c3255d59-0126-4fb4-b842-4628b74bd9f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_TradingSymbol_c3255d59-0126-4fb4-b842-4628b74bd9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6b764e1b-dea4-43a4-854c-5cf2ca21f0c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_SecurityExchangeName_6b764e1b-dea4-43a4-854c-5cf2ca21f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9bd667c3-d8be-4cf8-b944-4f6ff9cfb5b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityEmergingGrowthCompany_9bd667c3-d8be-4cf8-b944-4f6ff9cfb5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c2c7438d-f57f-4d09-8ec8-a74c1a51c0bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityAddressAddressLine1_c2c7438d-f57f-4d09-8ec8-a74c1a51c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_81a53d2b-753d-4ab1-a26e-52450de9508a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityAddressPostalZipCode_81a53d2b-753d-4ab1-a26e-52450de9508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c26af4ac-7fb4-4bee-afb1-11e80b2930bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityAddressCityOrTown_c26af4ac-7fb4-4bee-afb1-11e80b2930bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_21020a2f-eb3f-4556-bfe5-226a03dc620d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5ac70af2-d766-44b5-a4cc-6bcf28ea61a9" xlink:to="loc_dei_EntityAddressStateOrProvince_21020a2f-eb3f-4556-bfe5-226a03dc620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< 9<# 2(  A$! Q$!_\0
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MVM%MMH_KMHHHKX@]L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3VOFI,O]47[!G[1FI_M;_L>?L]?M'ZWHMIX=UWXM?#C1_$VOZ+ISSOIFG^(
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M)(9)$+*&R.'^%_QF\)?$ZQCCLKVWL/$T%NDFK>&;F=8]0M2% >YM(YO+EO\
M2W)5H;V&/]VLD<-['9WGF6R;>WK>P^K*I)4'55>5).T955%PC.26DW"+E&',
MGR*<^5KF=X]G#VGM;7GR\B;Z1O=I=KO?O8]=HHHK(L*_)3_@J1^SI\9OC[;_
M  >7X2>";KQB?#'_  G!UP6VIZ'IQL?[6'A<:?N_MG4].\\W!T^[VBW\TIY)
M\W8'3/ZUT4 ?QI>*/^">O[9UDCR/\ /&5RJ@L1IDNAZO(0."%BTO5[N1STPJ
M(Q/4 U\??$7]FW]H/P'YD_C'X(_%7PW;0L3+>:MX"\36MC&%))9KY]-^R!<9
M.XS8*_,"1S7]]U-*JPPR@C&,$ C'I@]O4=^] '\0G[.NKZSX:U?1]8T/4=0T
M36M+N(KBSU'3KF>QO[*YB) >*X@:.:%U^ZP##*DHX*,5/]57[)7[2\_Q=T.W
M\,^-GAA\?:?9ATOXXX[:U\56<"J);N*",)%:ZO;C]YJ-C B6\T1^WV*)#]IM
M;'V?Q_\ LY? [XG"23QE\,?".I:C(& UVWTFVTGQ)$2"/W7B+24LM:10<.8O
MMIA=E0R1OM KY5U?]E+4O@UJ%OXT^$^K:AJFFZ+>1:K'I%^/.U_1FM&,GG6E
MS:)$NN:<(@T5[I[6\%^]BT]OG5OM#Q  _1:OXS?^#K#_ )*Q_P $V/\ L9/B
MR/\ RX_@G^M?V+>&=<MO$WA[1/$%F1]FUG2[+48E#!]@N[>.<Q%EX9HF<QL1
MP64XK^0G_@Z^\*^)+-_V"/C(F@ZM?>!/ ?C;XF:/XIUG3[*6YM=)U/5KCX9:
M]H=C=W VV]M=:U8^%O$!TQ+J6!+J32[E$<E&K[[PQE%<:92G)1=2GF5.',TN
M:I/+,9&$$VTN:<FHQ6[DTEJSX[CV,I<+9CRW:C+!3E97M&&/PTI2:2?NQBFY
M/HKR>B;7]AEN,00C_IE'U_W!7"?$_P"%/PO^-'A*[\ _&#X?^#/B;X(U"ZLK
MR]\(^/O#ND^*O#E[=Z;<)>:?<7.BZW;7FG7$]E=1I<VLLEN[V\R+-$5=01_.
M/'_P=:_\$\XXXT;X9?M3DI&BDCP'\.B-RJ >OQ:!QD<'N*^!_P#@I=_P<=_
M_P#:7_90\6?"?]D"[_:S^"OQRUCQ+X)O_#WCZP.G?#6[L--TCQ'97VOV,/BO
MX??$^]\3VAU32XI[(VMG \-\)#;W8$+DTL!X=\9UL?A82RG'Y?"IB8)YA4A*
MG3PD'47^U5)TYJ<84HWFY0O)6NEU*Q?&O#%+"8B<<QP>-E"C.2P=.?-/$-0O
M[&,)1LW4T@DURW=G8_M$\"^!O!/PT\)Z)X$^'/A7P[X'\$^&K0:=X=\)^$M(
ML-!\.:%8B1YA9:3H^F06VGV%J)I99!!:P11"21V"[F)/\>O[ G_*T'^W7_V
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M<JK<28;,<RPV$K3XFS.K"G6FX2E3E[&$9I6VE*$TO.+Z(_IUKRKXY?&/P/\
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M0^ _"VM:M=K;0QVUNMSJ.I:5<WDZP6\45O")9G$<,4<2!8T51B_\,W_L\?\
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M*ES/]Y4:@M3]3O#WAOP]X2TBUT#PKH6C>&M"L?.^Q:+X?TNQT;2;,7%Q+=7
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MOW9--.FT[WM?4\P^$FN_%CQ%X3.H_&;X>^%/AEXQ_M2]@'AKP=\1+SXGZ/\
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140631346043040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Mar. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  05,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $Z)95@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !.B658?V4?[.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>.DT!H:CK91,GD)"8!.(6)=X6K?FCQ*C=V].6K1."!^ 8^Y?/
MGR4W.DH=$KZD$#&1Q7PSN,YGJ>.*'8BB!,CZ@$[E<DSXL;D+R2D:GVD/4>FC
MVB,(SN_!(2FC2,$$+.)"9&UCM-0)%85TQAN]X.-GZF:8T8 =.O24H2HK8.TT
M,9Z&KH$K8((1)I>_"V@6XES]$SMW@)V30[9+JN_[LJ_GW+A#!>_/3Z_SNH7U
MF937./[*5M(IXHI=)K_5Z\WVD;6"B]N"UP6_VPHA*R[%P\?D^L/O*NR"L3O[
MCXTO@FT#O^ZB_0)02P,$%     @ 3HEE6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R
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M4$L! A0#%     @ 3HEE6 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !.B658?V4?[.\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !.B658F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $Z)95A8>R.+9@0  *H0   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !.B658GZ ;\+$"  #B#   #0              @ &J#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $Z)95B7BKL<P    !,"   +              "
M 88/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $Z)95@<.&7J/P$  #P"   /
M              "  6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !.
MB658)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !.B65899!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20240305.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20240305.htm">cpix-20240305.htm</File>
    <File>cpix-20240305.xsd</File>
    <File>cpix-20240305_lab.xml</File>
    <File>cpix-20240305_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20240305.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20240305",
   "dts": {
    "inline": {
     "local": [
      "cpix-20240305.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20240305.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20240305_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20240305_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20240305.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20240305.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-009006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-009006-xbrl.zip
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MQL='37N!F@>>4[)7_4"U ]QF:X&@.\[0/RKY7/^LL=9&[).JQ@'8[?S[1,8
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M(8D/\R L?\=2R_+RE R$J=FDDO .%^:P5#X'NACOH.M4E>4.[ZC \385K6*
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M\;1Z\6I$O^51,ICI957?2V//&GO_W-->2]&VJ/YC5?*_<-7X/U!+ P04
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M6QL>J.L5?#7=X+\<NTED@#/<"*9MG3K$/R'P<%I?(9%O3^N 2YN+3 26$26
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M     &$R,#(S<31E>#DY,65A<FYI;F=S<F5L96%S92YH=&U02P$"% ,4
M" !.B6586%])D20/   C;0  $0              @ &720  8W!I>"TR,#(T
M,#,P-2YH=&U02P$"% ,4    " !.B658]QYYGH<"  #=!P  $0
M    @ 'J6   8W!I>"TR,#(T,#,P-2YX<V102P$"% ,4    " !.B6582^VL
M/&H*  !+7@  %0              @ &@6P  8W!I>"TR,#(T,#,P-5]L86(N
M>&UL4$L! A0#%     @ 3HEE6"]H:S>\!@  0S$  !4              ( !
M/68  &-P:7@M,C R-# S,#5?<')E+GAM;%!+!08     !0 % %$!   L;0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cpix-20240305_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20240305.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-03-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2525 West End Avenue, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
